Tiziana gains on starting human trial for Crohn's disease oral therapy

Tiziana Life Sciences

25/03/2022 12:01

** U.S.-listed shares of biotech co  TLSA.O  rise ~10% to
$1.22 before the bell - set to track their fourth session of
gains this week
    ** Co initiates early-stage study to evaluate its drug
foralumab, in the form of an oral capsule, in patients with
mild-to-moderate Crohn's Disease  urn:newsml:reuters.com:*:nGNX4CmfBX
    ** Crohn's Disease is a type of inflammatory bowel disease
that causes ulcers in the digestive tract 
    ** TLSA plans to begin patient enrollment for study in Q2,
targets study completion in Q4 
    ** Co is also testing an intranasal spray form of foralumab,
as a potential treatment for the neurological condition
secondary progressive multiple sclerosis (SPMS) in a separate
study  urn:newsml:reuters.com:*:nGNX45fNZs 
    ** Up to Thursday's close, TLSA up ~16% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))